Scientists at BC Children’s Hospital and the University of British Columbia have developed a gene therapy that programs a type of immune cell called T regulatory cells (Tregs) to protect transplanted tissues from rejection by the patient’s immune system.
The proof-of-concept study is published today in the Journal of Clinical Investigation print issue.
“With further research, Tregs could be given as a living drug to prevent immune attack of transplanted cells and organs,” says Dr. Megan Levings, the study’s principal investigator.
Dr. Levings is a scientist at the Child & Family Research Institute (CFRI) at BC Children’s Hospital where she leads the Childhood Diseases research theme, and she is a professor in the Department of Surgery at the University of British Columbia (UBC).
“This exciting discovery is the first step towards testing these cells in humans undergoing transplantation,” says Dr. Levings.
After transplantation, the patient’s body sometimes identifies the transplanted tissue as foreign and mounts an immune attack against it. For this reason, most transplant patients must take immune-suppressing medications for the rest of their lives.
In 2014, there were 2,433 solid organs transplanted in Canada and from 2010-2015, there were 52 pediatric solid organ transplants performed in British Columbia.
For this study, the scientists removed Tregs from blood donated by volunteers to the Canadian Blood Services. The scientists built a gene that makes a protein called CAR (chimeric antigen receptor). They used a harmless virus to insert the CAR gene into Tregs, which programmed the cells to recognize specific proteins commonly found on the surface of transplanted tissues. The normal role of Tregs is to turn off the immune response and prevent an immune response to healthy tissues. The scientists did a series of experiments that proved the modified Tregs could recognize transplanted tissues and protect them from the immune system.
A related concept is used in a type of cancer treatment called immunotherapy where the patient’s own immune cells are genetically programmed with the CAR gene to mount an immune response against tumour cells.
“We took this approach from cancer immunotherapy and we used it for the opposite purpose – to turn off unwanted immune responses,” says Dr. Levings.
“It’s a whole new age in medicine, and we’re doing cutting edge work right here in BC,” says Dr. Katherine MacDonald, the study’s first author. The research was the basis of Dr. MacDonald’s doctoral thesis while she was a UBC trainee supervised by Dr. Levings at CFRI.
“With this finding, it opens up the possibility to build a gene for any disease where the immune system is overactive,” says Dr. MacDonald.
This includes autoimmune diseases, which develop when the immune system destroys healthy tissues such as the insulin-producing cells of the pancreas in Type 1 diabetes or cells of the intestinal lining in inflammatory bowel disease.
The researchers say a decade of further work is needed to develop safe and targeted treatments using modified Tregs.
The Latest on: Transplant rejection
via Google News
The Latest on: Transplant rejection
- Dawn Thurman needs a second heart transplant. But insurance companies stand in the wayon September 5, 2019 at 1:18 pm
After giving birth to her son, Joshua, Dawn was diagnosed with an enlarged heart and told she needed a transplant ... time because Dawn has been on anti-rejection medicine for almost 31 years.
- BLOG: Preoperative considerations for cataract surgeryon September 5, 2019 at 9:21 am
Join us next month as we go into postop management, focusing on different corneal transplant rejection rates and keeping rejection from becoming failure.
- The global kidney transplantation therapeutics market at a CAGR of over 4% during the forecast periodon September 4, 2019 at 10:39 am
To overcome the challenge of transplant rejection, vendors have developed immunosuppressants. Thus, to reduce the risk and probability of the transplanted organ getting rejected, patients must ...
- New Drug Combination may Extend the Lives of Lung Transplant Patientson September 4, 2019 at 3:32 am
The most common cause of death following a lung transplant is a chronic rejection and to prevent this, patients will have to take immunosuppressive drugs for the rest of their lives. Immunosuppression ...
- Woman regains sight after stem cell transplanton August 30, 2019 at 11:52 pm
Rejection is a common problem in cornea transplants from deceased donors, with symptoms occurring in 20 per cent of cases. The doctors intend to carry out a second transplant this year and hope that, ...
- Global Kidney Transplantation Therapeutics Market 2019-2023 | Rising Prevalence of CKD and Renal Impairments to Boost Demand | Technavioon August 29, 2019 at 5:53 pm
Such advances are driving the demand for kidney transplantation. However, graft rejection is a major challenge associated with kidney transplantation. To overcome this challenge, vendors have ...
- Researchers perform 1st iPS cell cornea transplanton August 29, 2019 at 5:25 pm
The researchers said they performed the transplant on July 25 on the left ... The doctors said that the patient has not yet shown a rejection response and her vision has recovered so she no ...
- Immunosuppressive drug combo keeps lung transplant patients alive longeron August 29, 2019 at 8:49 am
Lung transplant patients have to take immunosuppressive drugs for the rest of their lives to stop chronic rejection of the organ. But these drugs make patients more susceptible to cancers and ...
- Osaka University team conducts world's first iPS transplant for corneal diseaseon August 29, 2019 at 3:09 am
Conventional corneal transplant operations are prone to rejection because immune cells get implanted along with the rest of the cornea. The sheets of corneal cells used by the team do not contain ...
- Drug combination could improve survival of lung transplant patientson August 28, 2019 at 11:56 am
"What we found could improve survival of lung transplant patients on a larger scale." To prevent chronic rejection, the most common cause of death after a lung transplant, patients must take ...
via Bing News